New Drugs and Devices for HF Therapy

Published: 31 July 2020

  • Views:

    Views Icon 297
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focuses on novel drugs and devices changing the treatment paradigm in Heart Failure management.

Agenda

  • Omecamtiv Mecarbil for Chronic HF - John Teerlink (University of San Francisco, San Francisco, US)
  • Devices for Functional MR beyond Mitraclip - Ralph Stephan von Bardeleben (University of Mainz, Mainz, DE)
  • Devices for Baroreflex Stimulation - Andrew Coats (Monash University, Melbourne, AU)
  • More on New Drugs and Devices on the Horizon - Stefan Anker (Charite University, Berlin, DE)

More from this programme

Part 1

Omecamtiv Mecarbil for Chronic HF

Part 2

Devices for Functional MR beyond Mitraclip

Part 3

Devices for Baroreflex Stimulation

Part 4

More on New Drugs and Devices on the Horizon

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile